Shareholders of Quoin Pharmaceuticals approved a proposal to amend beneficial ownership limitations for investors from previous private placements. The amendment allows investors to increase their ownership cap from 4.99% to up to 9.99% of outstanding ordinary shares upon written notice. This change applies to transactions consummated in October 2025 and August 2026 and aligns with both US and Israeli securities laws.
Quoin Pharmaceuticals announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its lead product candidate, QRX003, for the treatment of Peeling Skin Syndrome. This designation provides 10 years of market exclusivity in Europe upon potential marketing authorization and follows similar regulatory milestones in the US and Japan. The company remains on track to initiate the first-ever formal clinical study for Peeling Skin Syndrome before the end of 2026.